"We treat products containing cannabis or cannabis-derived compounds as we do any other FDA-regulated products — meaning they're subject to the same authorities and requirements as FDA-regulated products containing any other substance," Gottlieb wrote in aOn the heels of hemp legalization, regulators have fired a 'warning shot' to the $1 billion CBD industry
Gottlieb is expected to expand on precisely what that means during the meeting in April. Meanwhile, the analysts predict his plans will prioritize ensuring that some forms of hemp-derived CBD could be sold legally as foods or supplements, while also protecting pharmaceutical CBD applications., our weekly newsletter on pharma, biotech, and healthcare.
"In our view, Gottlieb's statement and testimony indicate that he is willing to take a flexible regulatory approach to foster the development of hemp products such as CBD," they wrote on Thursday. However, new laws may be required to do this, the analysts noted, meaning that the CBD legal haze will likely continue for several months.
"We continue to believe there will be a period of regulatory uncertainty over CBD products at the state and federal level for at least the next six months to a year," they wrote.SEE ALSO:
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »